CyberKnife Dose Escalation for Unfavorable and High-risk Prostate Cancer
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 100
- 试验地点
- 2
- 主要终点
- Bladder and Rectal Toxicity using NCI common toxicity criteria version 4.0
研究概览
简要总结
Stereotactic body radiation therapy (SBRT) has been employed in the treatment of prostate cancer. Multiple single institution experiences suggest high biochemical control rates with acceptable toxicity in low risk prostate cancer but efficacy data in unfavorable type prostate cancer is less convincing. CyberKnife-SBRT (CK-SBRT) can be used to escalate radiation dose delivery to the prostate while sparing normal tissue.
详细描述
The optimal radiation schedule for the curative treatment of prostate cancer remains unknown. Prostate cancer patients receiving radiation therapy are typically treated 5 days per week for 8-9 weeks. Recent data suggest that large radiation fraction sizes are radio-biologically favorable over lower fraction sizes in prostate cancer radiotherapy. The sensitivity of a tumor or normal tissue to fraction size of radiation can be approximated by the alpha-beta ratio. It has been suggested that the alpha/beta ratio for prostate cancer is actually as low as 1.5 implying that the current radiation therapy paradigm for prostate cancer treatment might be fundamentally flawed, as high fraction sizes would be expected to damage tumor more readily.
Typical prostate SBRT doses do not appear to have similar efficacy in higher risk prostate cancer suggesting even higher doses are required. Many techniques including dose escalated external beam radiation therapy (EBRT), proton therapy (PT) and brachytherapy have been employed to increase dose to the prostate. Data from the ASCEND-RT trial utilizing low dose rate brachytherapy boost showed a dramatic 21% improvement in biochemical control at 9 years favoring brachytherapy boost compared to conventional dose escalated EBRT radiation therapy. However, no corresponding benefit was identified in overall survival, incidence of bone metastases or prostate cancer specific mortality while a 3 fold increase in late urinary toxicity was noted.
SBRT is well tolerated with minimal acute and late side effects. In this protocol, CK-SBRT will be used to target the microscopic and gross disease in the prostate, seminal vesicles. An escalated dose of 40 Gy in 5 fractions will be delivered to the entire target volume while any nodules visible within the prostate gland on endorectal MRI will receive 50 Gy in 5 fractions.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed adenocarcinoma of the prostate diagnosed within 360 days of enrollment.
- •Prostate Specific Antigen (PSA) documented within 90 days prior to registration.
- •Clinical staging completed within 90 days of registration.
- •No Nodal or Distant Metastases documented on CT or MRI of the pelvis and bone scan.
- •Unfavorable Risk Prostate Carcinoma as Described is documented.
- •No prior pelvic radiotherapy.
- •No prior Trans-urethral resection of the prostate (TURP).
- •Prostate volume < 100 cc
- •American Urologic Association (AUA) score < 20
- •No recent (within 5 years) or concurrent cancers other than non-melanoma skin cancers.
- •Patient must have no medical or psychiatric illnesses that would interfere with treatment or follow-up.
- •No implanted hardware adjacent to the prostate that would prohibit appropriate treatment planning and treatment delivery is allowed.
- •Candidate for rectal spacer placement
排除标准
- •Other cancer diagnosis other than non-melanoma skin cancer with 5 years
- •Prostate size greater than 100cc
- •AUA greater than 20
- •Implanted hardware impacting imaging
- •Metastatic prostate cancer
- •Contraindication to hormone therapy
结局指标
主要结局
Bladder and Rectal Toxicity using NCI common toxicity criteria version 4.0
时间窗: 24 Months
Genitourinary or Bowel Toxicity as a result of radiation therapy will be reported using
次要结局
- Distant Failure(24 Months)
- Biochemical Disease Free Survival(24 Months)
- Duration of local control(24 Months)
- Disease Free Survival(24 Months)
- Overall Survival(5 years)
- Disease Specific Survival(24 Months)
研究者
Rachelle Lanciano M.D.
Principal Investigator
Crozer-Keystone Health System